Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

GlobeNewswire11-07

Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study Highlights Company’s Leadership and Progress in Developing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481977750?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Pq.TBs4PKmh_FSyMf8ETcw--~B/aD0xMTI7dz0zNjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fa4113865c027fc15f4677dd5a7eb358","is_english":true,"pubTime":"2024-11-07 19:40","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481977750","market":"us","top_or_hot":-1,"title":"Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024","media":"GlobeNewswire","content":"<div>\n<p>Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study\nHighlights Company’s Leadership and Progress in Developing ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cellectar-selected-present-data-phase-114000175.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cellectar-selected-present-data-phase-114000175.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study\nHighlights Company’s Leadership and Progress in Developing ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cellectar-selected-present-data-phase-114000175.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2362541273.HKD","symbol_name":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/cellectar-selected-present-data-phase-114000175.html","article_id":"2481977750","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Pq.TBs4PKmh_FSyMf8ETcw--~B/aD0xMTI7dz0zNjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fa4113865c027fc15f4677dd5a7eb358"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481977750","pubTimestamp":1730979600,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study. Highlights Company’s Leadership and Progress in Developing Iopofosine I 131 as Treatment for Waldenstrom’s Macroglobulinemia. FLORHAM PARK, N.J., Nov. 07, 2024  -- Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that new data from the company’s open-label Phase 2 CLOVER-WaM study of iopofosine I 131 as a potential treatment for Waldenstrom’s macroglobulinemia  will be highlighted in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition  taking place from December 7–10, 2024, in San Diego, California.Cellectar’s lead product candidate, iopofosine I 131, is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate. Iopofosine I","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1939255532.USD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (USD) ACC","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","WM":"美国废物管理","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","LU1892829315.USD":"FIDELITY FUNDS SUSTAINABLE WATER & WASTE \"A\" (USD) ACC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","BK4109":"特种化学制品","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","BK4585":"ETF&股票定投概念","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK4534":"瑞士信贷持仓","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","BK4139":"生物科技","WRD":"文远知行","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2041044095.USD":"Blackrock Circular Economy A2 USD","BK4566":"资本集团","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","LU1923621640.USD":"Natixis Thematics Water R/A USD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4120":"环境与设施服务","BK4588":"碎股","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","ASH":"亚什兰","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","CLRB":"Cellectar Biosciences Inc.","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC"},"translate_title":"Cellectar被选中在ASH 2024口头会议上展示2期CLOVER-WaM研究的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WRD":1,"ASH":1,"WM":1,"CLRB":0.9},"content_text":"Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study\nHighlights Company’s Leadership and Progress in Developing Iopofosine I 131 as Treatment for Waldenstrom’s Macroglobulinemia\nFLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that new data from the company’s open-label Phase 2 CLOVER-WaM study of iopofosine I 131 as a potential treatment for Waldenstrom’s macroglobulinemia (WM) will be highlighted in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024) taking place from December 7–10, 2024, in San Diego, California.\nCellectar’s lead product candidate, iopofosine I 131, is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate. Iopofosine I 131 is an investigational agent and has not been approved for use in any country, for any indication.\nWM is the dominant subtype lymphoplasmacytic lymphoma that remains incurable with available therapies. Treatment options beyond initial therapy are limited, underscoring the need for new therapies with novel mechanisms of action.\nThe pivotal CLOVER-WaM (NCT02952508) trial assessed the efficacy and safety of iopofosine I 131 in relapsed and refractory patients with WM who received at least 2 prior therapies. \n“We are honored to have the positive results from our CLOVER-WaM pivotal trial selected for oral presentation at ASH 2024. This highlights the need for novel class therapies for an often-overlooked patient population affected by this rare disease in which iopofosine I 131 has the potential to establish itself as the standard-of-care for relapsed/refractory patients,” said James Caruso, president and CEO of Cellectar. “As previously announced, we plan to submit a New Drug Application with the U.S. Food and Drug Administration in the coming months and, given the limited effective therapeutic alternatives available for WM patients, will be seeking priority review.”\nDetails for the presentations are as follows:\nPresenter: Ailawadhi, Sikander, M.D., professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo ClinicTitle: Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)Session: Oral Session Date: Monday, December 9, 2024 Session Time: 2:45 PM – 4:15 PMLocation: Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13Publication Number: 861\nThe complete abstract of the oral presentation can be accessed at the ASH 2024 website at 66th ASH Annual Meeting & Exposition - Hematology.org.\nIn-person participants at ASH 2024 may visit Cellectar Biosciences at Exhibit Booth #3300 in the Exhibit Hall (Halls B2-F at the San Diego Convention Center).\nAbout Waldenstrom’s Macroglobulinemia \nWaldenstrom’s Macroglobulinemia (WM) is a B-cell malignancy characterized by bone marrow infiltration with clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM) that remains incurable with available treatments. The prevalence in the US is approximately 26,000 with 1,500–1,900 patients being diagnosed annually. Approximately 11,500 patients require treatment in the relapsed or refractory setting and there are an estimated 4,700 patients requiring third line or greater therapy. There are also approximately 1,000 patients that have exhausted all current treatment options by third line because they are ineligible or intolerant to those existing therapies. Therefore, the total addressable market for third line or greater therapy is approximately 5,700 patients. There are no U.S. Food and Drug Administration (FDA) approved treatment options for patients progressing on BTKi therapy. BTKi therapies do not demonstrate complete response rates and require continuous treatment.\nNon-FDA approved treatments are used in more than 60% of patients. Over 50% of patients are treated with the same or similar treatment from prior lines of therapy. There is an established unmet need for new FDA-approved treatment like Iopofosine I-131 that provide a novel mechanism of action, increased deep durable responses, and time limited treatment, especially in heavily pretreated WM patients.\nAbout Cellectar Biosciences, Inc. \nCellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC™) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.\nThe company’s product pipeline includes lead asset, iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Additional radiotherapeutics are in development utilizing alpha emitters and Auger to target solid tumors.\nFor more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.\nForward-Looking Statement Disclaimer \nThis news release contains forward-looking statements. You can identify these statements by our use of words such as \"may,\" \"expect,\" \"believe,\" \"anticipate,\" \"intend,\" \"could,\" \"estimate,\" \"continue,\" \"plans,\" or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations regarding the CLOVER-WaM pivotal trial. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended June 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.\nContacts \nMEDIA:Christy MaginnBliss Bio Health703-297-7194cmaginn@blissbiohealth.com\nINVESTORS:Anne Marie FieldsPrecision AQ (formerly Stern IR)annemariefields@precisionaq.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481977750"}